Press release
Global Biomarkers Market is expected to record a positive CAGR of ~12% during the forecast period (2022-2028): Ken Research
The Global Biomarkers Market is expected to record a positive CAGR of ~12% during the forecast period (2022-2028), due to the rising prevalence of chronic and neurodegenerative diseases. The ongoing Covid-19 pandemic significantly impacts plasma and sera proteomes, which holds a promising result for the faster recognition of biomarkers for diagnosis, prognosis, and/or therapeutic targeting in the ongoing rapidly growing pandemic that necessitates a rapid scientific response thereby benefitting the market.For more information, request a free sample: https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDk2
Key Growth Drivers
The growing popularity of remote technologies such as wearables and mobile applications is fuelling the digital biomarker market (DBMs) growth. Additionally, increasing digitization across the healthcare industry has transformed medical science, diagnostics, and therapeutics, resulting in rapid advancements in the development and adoption of Digital Health Technologies (DHT) by the healthcare continuum.
For instance, according to Oracle Cerner, a Texas-based technology company, the digital health innovation space has grown significantly over the last ten years. Global financial and corporate markets invested USD 44 billion in 2021, up from USD 2 billion in 2011.
The emergence of advanced technologies such as artificial intelligence (AI) is likely to create new opportunities for the biomarkers providers, as AI can assist clinicians in identifying risk factors for developing heart failure, monitoring care, defining prognosis, and creating druggable targets.
For instance, in May 2022, Imagene AI, an Israel-based digital biomarker company, received USD 21.5 million in funding to emphasize precision medicine in cancer care. In February 2022, Koneksa, a U.S.-based company that designs digital biomarkers, raised USD 45 million in Series C financing to accelerate the emergence of its digital biomarker platform.
Individual privacy concerns and the lack of validation procedures are expected to hinder the biomarkers market's growth.
Furthermore, it is difficult to foresee how the Covid-19 virus will manifest in an individual as the symptoms of the virus range from mild fever and cough to acute respiratory distress syndrome (ARDS) and death, and the virus has an impulsive course. This variability has prompted an urgent pursuit for biomarkers of disease severity to deal with patients appropriately and prevent fatal complications.
Key Trends by Market Segment
By Types: Molecular Biomarkers hold the largest share of the Global Biomarkers Market.
Molecular Biomarkers are easily measurable as they emerge from immunology and neurobiology and can competently support other disease characteristics as well.
In addition, they also can identify individuals who are predisposed to the disease.
For instance, according to Experimental and Therapeutic Medicine, a U.S.-based journal devoted to laboratory and clinical medicine, some molecular biomarkers, such as p16, and Ki-67, have a higher positive predictive value (PPV) of 46.20% and 32.40% respectively, which can improve treatment for many thousands of women every year.
By Application: The Diagnostics application segment accounts for the majority share of the Global Biomarkers Market.
Biomarkers are widely used in the treatment and diagnosis of cardiovascular disease, infectious diseases, immunological and genetic disorders, cancer, and other diseases.
In addition, their use in research emerged from the need for more precise observation of contaminants in the predictive pathway of disease and has the potency to provide information on exposure uptake.
Biomarkers have also been increasingly used by neuroscientists to help with the diagnosis and treatment of neurological disorders, along with investigating their causative factors.
By Disease: The oncology segment accounted for the largest share in the market in 2020, owing to a rise in cancer patients worldwide and an unmet need for more precise, personalized targeted therapies for cancer patients. As per forecast by International Agency for Research on Cancer (IARC), the cancer cases are expected to significantly increase in all geographic regions of world during the next 20 years.
The dramatic shift toward precision medicines for treating cancer due to the absence of standard diagnosis and therapy/treatment is one of the major contributing factors to the demand for cancer biomarkers.
Furthermore, biomarkers have numerous legitimate applications in oncology, which is a branch of medicine that specializes in cancer diagnosis and treatment.
Assessing an individual's risk of developing cancer
Determine the prognosis
Predicting response to treatment that a given therapy will work for a patient
Monitoring disease progression to ascertain if a therapy is working
Visit this Link Request for custom report: https://www.kenresearch.com/ask-customization.php?Frmdetails=NTkyNDk2
By Geography: North America accounts for the largest share among all regions within the Global Biomarkers market.
Rapid advancements in the development and adoption of digital health technologies (DHT) across North America, notably in the United States, are one of the major contributing factors to the growth of digital biomarkers,
For instance, according to JTO Clinical and Research Reports, an open access journal of the International Association for the Study of Lung Cancer, a total of 17,513 patients (91.6% from community-based practices) in the U.S. were exempt with 83,064 genomic biomarker tests captured between 2015 and 2021.
In addition, the ratio of patients who received biomarker testing using next-generation sequencing (NGS)-based methods, a technique that allows healthcare professionals to assess multiple cancer genes at the same time, rose from 28.3% in 2015 to 68.1% in 2020.
Increasing regional government initiatives and strategies for biomarker development and regulatory science activities across the healthcare industry are also propelling the biomarkers market growth in North America.
For instance, in July 2022, the food and drug administration (FDA) stated that it and multiple medical product developers are keen on developing novel biomarkers for use in assessment to improve clinical trial accuracy and efficiency.
The Asia Pacific region is expected to grow at the fastest CAGR during the forecasted period 2022-2028, owing to the government's increased emphasis on improving healthcare infrastructure, the adoption of smart medical devices such as wearables, and the rising prevalence of diseases causing high rates of mortality and morbidity.
To more about industry trends, Request a free Expert call: https://www.kenresearch.com/talk-to-expert.php
Competitive Landscape
The Global Biomarkers market is highly competitive with ~800 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche in pharma and diagnostics solutions, and technologies, such as vitro analyses of DNA variation, RNA expression, metabolite quantification, vivo measurements of biological processes, and others, for end-user industries. The biomarkers market's growth is heavily reliant on technological advancement and R&D investment. Nowadays, numerous pharmaceutical companies, including Pfizer, Roche, Merck, Novartis, and Johnson & Johnson are investing in R&D or drug research, and governments are also making significant investments in cancer research.
For More Information on the Research Report, refer to below links: -
https://www.kenresearch.com/business-research/global-biomarkers-market-outlook-2028/
Country-Niche players control about ~77% of the market, while regional players hold a share of ~18%. Some of the major players in the market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Epigenomics AG, Johnson & Johnson Services, Inc., PerkinElmer Inc., Enzo Biochem, Inc., General Electric and among others.
Recent Developments Related to Major Players and Organizations
In March 2022, Roche, a Switzerland-based pharmaceuticals company, announced its collaboration with Bristol Myers Squibb, a pharmaceutical industry company based in the United States, to promote the development of two biomarkers for use in drug testing through the development and deployment of two new digital pathology algorithms for biomarker analysis and clinicians.
In August 2022, Thermo Fisher Scientific, a U.S.-based manufacturer of analytical laboratory instruments, launched CE-IVD (IVDD), a next-generation sequencing test and analysis software to improve accessibility to precision oncology biomarker testing.
In August 2022, Qiagen, a German provider of sample and assay technologies for molecular diagnostics, introduced new next-generation sequencing (NGS) solutions, 'QIAseq Targeted DNA Pro Panels' and 'the QIAseq UPXome RNA Library Kit' which significantly improve DNA variant detection and RNA sequencing of moderate samples.
In February 2022, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, a non-profit organization based in the United States, initiate a new project entitled "Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)" to determine an adequate blood test to assess a protein that is essential in the early detection of rare neurodegenerative disorders.
In February 2022, Abbott Laboratories, a medical device company located in the United States, launched consumer bio wearables named 'Lingo,' which can track body sensory information to help users better understand their overall health and take measures to improve it.
Conclusion
The Global Biomarkers Market is forecasted to continue an exponential growth that is witnessed since 2019, during the forecast period also, primarily driven by the rising prevalence of chronic and neurodegenerative diseases and the growing popularity of remote technologies such as wearables and mobile applications. Though the market is highly competitive with over ~800 participants, few country-niche players control the dominant share.
Ken Research has recently published report titled, Global Biomarkers Market Size, Segments, Outlook, and Revenue Forecast 2022-2028. In addition, the report also covers the market size for each of the five regions' biomarker markets. The revenue used to size and forecast the market for each segment is USD billion.
Market Taxonomy
By Type
Molecular
Radiographic
Histologic
Physiologic
By Application
Diagnostics (Including Disease Susceptibility/Risk Assessment)
Drug Discovery & Development
Personalized Medicine
By Disease
Oncology/Cancer
Cardiovascular Disease
Neurological Disorders
Immunological Disorders
By Geography
North America (U.S., Canada, Mexico)
Europe (Germany, UK, France, Italy, Spain)
Asia Pacific (China, Japan, India, Australia, South Korea)
Latin America Middle East and Africa (LAMEA)
Ken Research Pvt. Ltd.,
Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana - 122001, India
Ken Research is a Market Research and Consulting Firm, based out of India, Indonesia and UAE. Since 2011, we have been assisting clients globally with our Syndicate and Bespoke Market Research and Advisory Services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Biomarkers Market is expected to record a positive CAGR of ~12% during the forecast period (2022-2028): Ken Research here
News-ID: 2862700 • Views: …
More Releases from Ken Research Pvt .Ltd

Ken Research Stated UAE Lubricants Market to Reached USD 1 Billion
Comprehensive market analysis maps demand pockets, re-export corridors, and strategic imperatives across automotive, industrial, and marine end-use in the UAE's lubricant ecosystem.
Delhi, India - October 6, 2025 - Ken Research released its strategic market analysis titled "UAE Lubricants Market Outlook to 2030," revealing that the current market size is valued at USD 1 billion, based on a five-year historical analysis. The comprehensive analysis details how the market is expected to…

India Apparel Market Crosses USD 68 Billion Milestone - Latest Insights by Ken R …
Comprehensive market analysis maps consumer evolution, retail transformation, and policy-led competitiveness shaping India's apparel ecosystem.
Delhi, India - October 6, 2025 - Ken Research released its strategic market analysis titled "India Apparel Market Outlook to 2030," revealing that the current market size is valued at USD 68 billion, based on a five-year historical analysis. The detailed analysis outlines how the market is poised to expand, driven by rising disposable incomes, rapid…

Philippines E-commerce Logistics Market - Ken Research Stated the Sector is Valu …
Comprehensive market analysis maps exponential growth trajectory, investment opportunities, and strategic imperatives for industry leaders in the Philippines' rapidly evolving e-commerce logistics ecosystem.
Delhi, India - October 6, 2025 - Ken Research released its strategic market analysis titled "Philippines E-commerce Logistics Market Outlook to 2028," revealing that the current market size is valued at over USD 1700 million, based on a five-year historical analysis. The comprehensive analysis details how the market…

Budaun & Pilibhit Oncology Market - Ken Research Stated the Sector is Recorded a …
Comprehensive analysis charts rising incidence, capacity build-out, and investment pathways across two high-potential Uttar Pradesh districts.
Delhi, India - October 3, 2025 - Ken Research released its strategic market analysis titled "Budaun & Pilibhit Oncology Market Outlook to 2029," revealing that the current market size is recorded at 8,870 cases, based on a five-year historical analysis. The comprehensive analysis details how the market is expected to expand, driven by rising cancer…
More Releases for Biomarker
Transformative Trends Impacting the Multiplex Biomarker Imaging Market Landscape …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Multiplex Biomarker Imaging Market Size By 2025?
In recent times, the size of the multiplex biomarker imaging market has experienced significant growth. There is an expected rise from $0.49 billion in 2024 to $0.54 billion in 2025, with a compound annual growth rate (CAGR) of…
Blood-Based Biomarker Market Beyond the Needle: The Future of Diagnostics Lies i …
Blood-Based Biomarker Market worth $51.71 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Blood-Based Biomarker Market - (By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic,…
Biomarker Discovery Outsourcing Services Market Biomarker Discovery Outsourcing: …
Biomarker Discovery Outsourcing Services Market to reach over USD 52.82 billion by the year 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers And Surrogate Endpoints),
Therapeutic Area (Oncology, Neurology, Cardiology, Autoimmune Diseases), Discovery Phase (Biomarker Identification, Biomarker Validation,…
Biomarker and Companion Diagnostics Conference | Modeling Strategies for Biomark …
MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 20-21 June 2024 in Boston, USA.
Register Now @ https://events.marketsandmarkets.com/2nd-annual-biomarker-and-companion-diagnostics-conference-usa-edition/register
MarketsandMarkets 5th Annual Biomarker and Companion Diagnostics Conference:
Immerse yourself in the realm of biomarkers at our flagship event, where industry leaders and experts converge to propel innovation in healthcare, diagnostics, and personalized medicine. This conference serves as a dynamic platform for collaboration, knowledge sharing, and exploration of cutting-edge…
Central Nervous System (CNS) Biomarkers Market Analysis Forecast 2023-2028 Globa …
The Central Nervous System (CNS) biomarkers market refers to the market for biomarkers used in the diagnosis, prognosis, and monitoring of diseases and disorders affecting the central nervous system. The central nervous system includes the brain and spinal cord, and disorders affecting this system can have significant impacts on an individual's health and well-being.
CNS biomarkers are measurable indicators that can provide information about the state of the central nervous system,…
Multiplex Biomarker Imaging Market - Advanced Solutions for Comprehensive Biomar …
Newark, New Castle, USA: The "Multiplex Biomarker Imaging Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiplex Biomarker Imaging Market: https://www.growthplusreports.com/report/multiplex-biomarker-imaging-market/8558
This latest report researches the industry structure,…